Biotech entity
Every one of those 2 sits in a single category, fda-approval. BPC-157 is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Each story carries 2.5 original sources on average, compared with 2.3 for the broader beat in this window.
Last mentioned: Aug 3, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, fda-approval. BPC-157 is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Each story carries 2.5 original sources on average, compared with 2.3 for the broader beat in this window. At 5.5, the average consequence score sits below the same-window beat average of 5.8. We currently track 2 Biotech stories that mention MOTS-c, published between August 1, 2026 and August 3, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 33 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering MOTS-c. Shared-story counts are live from our verified record — not editorial picks.
PCAC Votes to Recommend Six Peptides
The committee votes to recommend BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax for inclusion on the 503A Bulks List, culminating the multi-day review.
FDA PCAC Public Meeting Begins
The Pharmacy Compounding Advisory Committee commences a two-day meeting to review nominations of bulk drug substances, including six peptide candidates, for the 503A Bulks List.
FDA Advisory Panel Hearing
Marathon hearing votes 6-1 to back compounding of six peptide therapies, including BPC-157, TB-500, and MOTS-c, despite FDA scientists' concerns.
Despite FDA scientists’ safety concerns, an advisory panel overwhelmingly backed six peptide therapies for compounding, including TB-500 and MOTS-c. The biotech sector watches closely as the FDA prepares for rulemaking, which may redefine the boundary between pharmaceutical development and pharmacy compounding.
Source: wknofm.org · wmuk.org
An FDA advisory committee endorsed six peptide substances for the 503A Bulks List, a milestone that could validate the therapeutic potential of BPC-157, TB-500, MOTS-c and others. Vanta is leveraging this to build a biotech platform combining peptide manufacturing with its consumer health portfolio.
MOTS-c is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
